Seeking Alpha

Threshold Pharmaceuticals (THLD -5.4%) succumbs to profit taking, after bouncing back strong...

Threshold Pharmaceuticals (THLD -5.4%) succumbs to profit taking, after bouncing back strong from Monday's selloff over poor clinical trial results for its hypoxia-targeted drug TH-302. Separately, Maxim initiated coverage on the stock today with a Buy, saying that TH-302 is currently in a phase III trial as a first-line treatment with doxorubicin for advanced soft tissue sarcoma as well, and there's a good chance for a significant improvement in overall survival.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs